Q-omics provides the consensus-scored MT-TL2 profile across patient tissues and cancer cell-line models. MT-TL2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MT-TL2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MT-TL2 RNA expression shows 7,384 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight BRCA, COAD, and PCPG as cancer lineages where MT-TL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-TL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-TL2 survival associations across molecular data types. MT-TL2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-TL2 RNA expression–survival associations across cancer types. High MT-TL2 expression shows unfavorable associations in BRCA, OV and PRAD, but favorable associations in PAAD, ACC and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MT-TL2 RNA expression.
This table summarizes MT-TL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MT-TL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-TL2 shows lower tumor expression in CHOL, THCA and KIRP and higher tumor expression in COAD, LUAD and UCEC. The COAD box plot shows higher MT-TL2 RNA expression in tumor versus normal tissue (log2 FC = +0.596, t-test p = .006).
This table shows molecular features associated with MT-TL2 in patient tissues and cancer cell lines. In patient samples, MT-TL2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
